Connect with us

Latest News

Johnson & Johnson deserves more credit for another healthy quarter and strong guidance

Published

on

The new year has been tough on pharmaceutical stocks, including JNJ. But it should not be read as an indictment on the company’s operations.

Continue Reading
Comments